# NANOVIRICIDES, INC. (NNVC) — capital_raise/atm_program [completed]
Source: SEC API (secapi.ai) · situation sit_dbc0068e2540e6c6e88e · retrieved 2026-08-11T16:11:02.759Z

## Overview
NanoViricides, Inc. is a pharmaceutical company developing antiviral therapeutics.

NanoViricides, Inc. completed a registered direct offering on July 27, 2026, issuing 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants to purchase 100,000 shares at $1.52999 per warrant, and common warrants to purchase 2,516,339 shares at an exercise price of $1.75 per share (exercisable six months from issuance and expiring 5.5 years from issuance). The aggregate gross proceeds were approximately $3.8 million. The company agreed to a 60-day lock-up on new issuances and to file a resale registration statement within 30 days. D. Boral Capital LLC served as placement agent and received a 7.0% fee plus up to $50,000 in reimbursable expenses.

## Terms
- Counterparty: Armistice Capital Master Fund Ltd (investor) · Deal value: $3.8M · Consideration: cash · Price/share: $1.53

## Key dates
- Completed 2026-07-17

## Timeline
- 2026-07-17 · 8-K (0001104659-26-084668): 8-K - NANOVIRICIDES, INC. — *NanoViricides, Inc. is a Delaware corporation engaged in the development of pharmaceutical preparations.* NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC on July 17, 2026, pursuant to which the Company may offer and sell shares of its common stock in an "at the market" offering under its existing Form S-3 registration statement (File No. 333-296550), initially filed June 5, 2026 and declared effective June 15, 2026. The Company will pay D. Boral Capital a commission equal to 2.0% of the aggregate gross proceeds from each sale of Placement Shares. The maximum offering size is $4,018,069 of common stock, par value $0.00001 per share.
  https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-084668.txt
- 2026-07-30 · 8-K (0001104659-26-088393): 8-K - NANOVIRICIDES, INC. — *NanoViricides, Inc. is a pharmaceutical company developing antiviral therapeutics.* NanoViricides, Inc. completed a registered direct offering on July 27, 2026, issuing 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants to purchase 100,000 shares at $1.52999 per warrant, and common warrants to purchase 2,516,339 shares at an exercise price of $1.75 per share (exercisable six months from issuance and expiring 5.5 years from issuance). The aggregate gross proceeds were approximately $3.8 million. The company agreed to a 60-day lock-up on new issuances and to file a resale registration statement within 30 days. D. Boral Capital LLC served as placement agent and received a 7.0% fee plus up to $50,000 in reimbursable expenses.
  https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-088393.txt

## Citations
- 0001104659-26-084668 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926084668
- 0001104659-26-088393 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926088393